MEDINDIA
English
हिन्दी
Español
français
中文
A court ruling allows NeoGenomics to expand its cancer test, while Natera remains strong with key patents and growing revenues.
Natera Provides Update on Patent Litigation with NeoGenomics
Go to source).
Lifetime Risk Calculator for Cancers
What are your chances for developing some common cancers in your lifetime - find out now.
What are your chances for developing some common cancers in your lifetime - find out now.
TOP INSIGHT
Did You Know
Natera holds over 500 patents worldwide, making it one of the strongest intellectual property holders in cancer diagnostics
#cancer #medindia
More Focus on Cancer Testing
CEO Tony Zook welcomed the decision, noting the company’s focus on providing more cancer testing options. While profits remain a challenge, the company is steadily growing and staying financially stable.
Future of Cancer Treatment Lays With Custom Vaccines
Researchers at Ludwig Cancer Research developed a comprehensive AI-driven system to analyze tumors and create personalized cancer vaccines based on T-cell targets.
Researchers at Ludwig Cancer Research developed a comprehensive AI-driven system to analyze tumors and create personalized cancer vaccines based on T-cell targets.
Holds Over 500 Patents
For Natera, the setback is small. It still controls more than 500 patents, including one powerful patent (‘035) that previously blocked NeoGenomics’ older version of the RaDaR test. Natera may appeal the ruling, but it continues to grow, with Q2 revenue up 32% to $546.6 million due to increased demand for its cancer tests.
3D Tumor Models Enables Study of How Cancer Works
The possibilities for bioprinting extend beyond the lab. Researchers used a 3D cancer model and treated it with chemotherapy and with immunotherapy.
The possibilities for bioprinting extend beyond the lab. Researchers used a 3D cancer model and treated it with chemotherapy and with immunotherapy.
From Two Billion To Seven Billion
The MRD testing market is expected to soar from $2 billion in 2025 to $7 billion by 2033. Both Natera and NeoGenomics are racing to stay ahead, with success depending on strong innovation, patent protection, and wider insurance coverage.Reference:
- Natera Provides Update on Patent Litigation with NeoGenomics - (https://www.natera.com/company/news/natera-provides-update-on-patent-litigation-with-neogenomics/)
Source-Natera
Cancer Treatment With 3D Bioprinting Technology
Bioprinting and microfluidic chip technology were combined to create realistic 3D tumor models, which will help improve understanding of tumors.
Bioprinting and microfluidic chip technology were combined to create realistic 3D tumor models, which will help improve understanding of tumors.
Email
